Abstract. The Danazol is widely used in the treatment of endometriosis and it is increasingly applied in the manage¬ ment of other gynaecological disorders (Dmowski 1979; Jenkin 1979 Oestradiol : 1,3,5(10)-oestratriene-3,1.7ß-diol.
times daily, from the 3rd to the 23rd day of the cycle to normally menstruating women exhibited the following actions on the human endometrium: significantly reduced cytosol oestrogen and progestin receptor concentrations, and declined 17\g=b\-hydroxysteroiddehydrogenase activity. Very similar results were obtained during medroxyprogesterone acetate (100 mg daily) treatment for the same period of time. Danazol administration did not decrease circulating gonadotrophin levels but clearly suppressed luteal serum oestradiol and progesterone concentrations. Danazol was found to bind in vitro to endometrial progestin receptor with an affinity approximately 3% of that of progesterone. These findings are compatible with the notion that a local progestin-like rather than a systemic action of danazol is the way by which its therapeutic effect is exerted. This may be potentiated by the suppression of circulating oestradiol levels.
Danazol is widely used in the treatment of endometriosis and it is increasingly applied in the manage¬ ment of other gynaecological disorders (Dmowski 1979; Jenkin 1979) . The mechanism of action of danazol is poorly understood. Danazol was shown to suppress elevated gonadotrophin levels in postmenopausal women, but this antigonadotrophic effect is not clear in a number of physiological and experimental conditions (Jenkin 1979) . Danazol has also been reported to interact with a number of steroid receptors (Barbieri et al. 1979; Chamness et al. 1980) , and to exert inhibitory effects on gonadal steroidogenesis (Barbieri et al. 1977a,b) . The mi¬ nor interaction of danazol with progestin receptor has been interpreted as an antiprogestational pro¬ perty of danazol (Jenkin 1979) .
To extend our studies on the mechanism of progestin action in human endometrium (Hammond et al. 1977a ). All these assays included low, medium and high concentration control sera among the analytical samples.
The concentrations of oestradiol and progesterone were measured by radioimmunoassay using kits kindly donated by Nordiclab Oy, Oulu, Finland, following the manufacturer's instructions and adopting a semi-auto¬ mated processing of the tubes (Hammond et al. 1977b ). Low and high concentration control sera were run in parallel with the samples.
Processing of tissue samples
Tissue samples were washed with ice-cold buffer TEND-10G (10 mM Tris-HCl, pH 7.5 at 23°C, 1.5 mM EDTA, 3 mM NaN3, 2 mM dithiothreitol, and 10%, v/v, glycerol), cut with scissors into small pieces and then homogenized in the TEND-10G buffer (4-6 ml/g tissue wet weight).
All procedures
were carried out at 0-4°C. The homogenate was centrifuged at 800 x g for 15 min, and the supernatant was divided into three parts. The first part was used for the determination of protein content, the second for the immediate determination of 17ß-hydroxysteroid dehydrogenase and the third was centrifuged at 105 000 x g for 60 min to get the cytosol fraction, which was used for the determination of oestrogen and pro¬ gestin receptors.
The 800 g-sediment was re-homogenized twice in TEND-10G buffer (8 ml/g tissue wet weight) containing 1 mM MgClî using a motor-driven Teflon-glass homogenizer with intermittent centrifugation at 800 x g for 15 min. The suspension after the third homogenization was used for determination of DNA, and nuclear oestro¬ gen and progestin receptor levels.
Measurement of 17ß-hydroxysteroid dehydrogenase activity 17ß-Hydroxysteroid dehydrogenase activity was meas¬ ured as described by Tseng & Gurpide (1975) . One ml of the 800 g'-supernatant (protein content about 1 mg/ml) in TEND-10G buffer containing NAD+ (1.4 umol/1) and
[3H]oestradiol (3 x 105cpm, 37 nmol/1) was incubated for 18 h at 4°C, and the following procedures were per¬ formed as outlined above for the oestrogen receptor. (7) 8.23 ± 0.10 (8) 9.90 ± 0.97*(4) 7.66 ± 0.93 (7) 16.70 ± 4.40 (8) 16.45 ± 7.75 (4) 6.11 ±0.78* (7) 13.00 ± 2.49 (8) 11.70 ±2.57 (4) 6.59 ± 1.07* (7) 3.96 ±0.73 (8) 7.70 ± 4.08 (4) 4.24 ±0.67 (7) 4.63 ± 0.94 (8) 5.10 ±2.07 (4) 4.74 ±0.81 (7) 6.99 ± 1.72 (8) 4.93 ± 1.50 (4) 7.41 ± 1.45 (7) 0.13 ± 0.03 (8) 0.09 ± 0.04 (4) 0.07 ± 0.02 (7) 0.50 ±0.17 (8) 0.37 ±0.18 (4) 0.26 ±0.17 (7) 0.36 ± 0.07 (8) 0.08 ± 0.02* (4) 0.16 ± 0.06 (7) 0.76 ± .
Danazol or MPA treatments did not significantly alter nuclear ER and PR levels. A significant de¬ crease in the endometrial I7ß-HSD activity was associated with the long-term administration of both danazol and MPA (Fig. 1 ). This effect is in sharp contrast to the more acute effects of proge¬ sterone leading to enhanced 17ß-HSD activity in the endometrium (Tseng & Gurpide 1975) , but it is possible that the ultimate biological action of progestins given for a long time is to terminate rather than maintain an acute progestin effect on the endometrium. Danazol seems also to have an acute progestin-like effect, as it induced early secretory changes in the endometrium of an ovariectomized woman on cyclic stilboestrol therapy (Wentz et al. 1976 ).
That danazol really has progesterone-like pro¬ perties was further supported by experiments in which large doses of danazol were given alone or in combination with progesterone to rabbit for 5 days (Kokko, .
Collectively, on the basis of our results it is very difficult to assign an antiprogestational activity for danazol. Rather, when danazol is given in doses used for the treatment of endometriosis (Dmowski 1979; Jenkin 1979) , it exhibits actions that are very similar to those seen during a long-term treatment with high doses of an active progestin such as MPA.
